fda regulations semaglutide approves first-ever oral GLP-1RA for obesity and chronic weight management. Meet Wegovy (semaglutide) tablets. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults Hims Inc. - Novo Nordisk's

Real-world observations suggest that properly dosed sublingual semaglutide at therapeutic levels can produce meaningful weight loss, typically in the range of 8% to 15% body weight over 12 to 16 weeks

For most patients, nausea is the most disruptive but it almost always improves

This biological change means your stomach sends fullness messages to your brain faster and more powerfully than before treatment

Although GLP-1s are generally safe for the liver, its important to check, especially before compounded meds Kidney function: to watch for stress on the kidneys, which can be exacerbated by GLP-1-induced dehydration and nausea, especially in older adults or those with preexisting conditions [1] Thyroid markers : to screen for an under-functioning thyroid gland, which can mimic or worsen weight gain

It has been hypothesized that reduced IL-17 expression may contribute to this improvement

Preference for oral and injectable GLP-1 RA therapy profiles in japanese patients with type 2 diabetes: a discrete choice experiment